Relay Therapeutics, Inc. (RLAY)

Market Cap	2.59B
Revenue (ttm)	1.70M
Net Income (ttm)	-290.46M
Shares Out	120.90M
EPS (ttm)	-2.66
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	84,267
Open	21.39
Previous Close	21.46
Day's Range	21.14 - 21.78
52-Week Range	12.65 - 35.36
Beta	1.01
Analysts	Buy
Price Target	37.94 (+76.79%)
Earnings Date	Feb 22, 2023

About RLAY

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibit...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 16, 2020
• Employees: 320
• Stock Exchange: NASDAQ
• Ticker Symbol: RLAY

Financial Performance

In 2021, RLAY's revenue was $3.03 million, a decrease of -96.34% compared to the previous year's $82.65 million. Losses were -$363.87 million, 58.1% more than in 2020.

Analyst Forecast

According to 17 analysts, the average rating for RLAY stock is "Buy." The 12-month stock price forecast is $37.94, which is an increase of 76.79% from the latest price.

Price Target

$37.94

(76.79% upside)

Analyst Consensus: Buy